AcelRx Pharmaceuticals, Inc. (ACRX)
-NasdaqGM 6.68 
0.51(7.09%) May 17, 4:00PM EDT
| Prev Close: | 7.19 |
|---|
| Open: | 7.22 |
|---|
| Bid: | 5.71 x 1700 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 10.14 |
|---|
| Beta: | 1.63 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 6.50 - 7.26 |
|---|
| 52wk Range: | 2.27 - 7.30 |
|---|
| Volume: | 337,468 |
|---|
| Avg Vol (3m): | 304,059 |
|---|
| Market Cap: | 248.74M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.47 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Nasdaq stocks posting largest percentage decreasesAP(Fri, May 17)
- AcelRx Pharmaceuticals to Present at the UBS Global Healthcare ConferencePR Newswire(Thu, May 16)
- ACELRX PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Tue, May 14)
- ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExEDGAR Online(Fri, May 10)
- ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements anEDGAR Online(Thu, May 9)
- AcelRx Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 8)
- AcelRx Pharmaceuticals Reports First Quarter 2013 Financial ResultsPR Newswire(Wed, May 8)
- ACELRX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 8)
- Q1 2013 AcelRx Pharmaceuticals, Inc. Earnings Release - After Market CloseCCBN(Wed, May 8)
- Drug companies attempt to make painkillers that can't be abused, WSJ reportstheflyonthewall.com(Mon, May 6)
- AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013PR Newswire(Fri, May 3)
- AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical MeetingPR Newswire(Thu, May 2)
- Major Pharma Companies Refocus R&D Efforts, Aim to Replace Lost Revenues: Expert Analyst Ian Somaiya Discusses M&A Drivers with The Wall Street TranscriptWall Street Transcript(Tue, Apr 30)
- 3 Healthcare Stock Stories for Midweek Investment Wellnessat Wall St. Cheat Sheet(Wed, Apr 24)
- GM Sparks Electric Vehicle Program, Sprint Beats Expectations, and 3 Other Hot Stocksat Wall St. Cheat Sheet(Wed, Apr 24)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 89.10 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.97 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.22 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain.
View More